Urol. praxi. 2018;19(2):72-75 | DOI: 10.36290/uro.2018.060

Proton-beam therapy controversies in prostate cancor

prof. MUDr. Jiří Petera, Ph.D.1, doc. MUDr. Miloš Broďák, Ph.D.2, MUDr. Jan Pokorný, FEBU, MBA3, MUDr. Michaela Matoušková4, Vlasta Králová4
1 Klinika onkologie a radioterapie, FN a LF UK Hradec Králové
2 Urologická klinika, FN a LF UK Hradec Králové
3 Urologické oddělení Nemocnice v Karlových Varech
4 Urocentrum Praha

The authors describe the possibilities of radiotherapy of prostate cancer and focus on certain controversies associated withproton therapy in this indication. They bring up to date published data on the results and risks associated with proton therapyin prostate irradiation. The work also contains presented case studies of patients with proton-related complications who havebeen or are being treated for urology.

Keywords: radiotherapy, proton-beam therapy, radical prostatectomy

Published: May 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petera J, Broďák M, Pokorný J, Matoušková M, Králová V. Proton-beam therapy controversies in prostate cancor. Urol. praxi. 2018;19(2):72-75. doi: 10.36290/uro.2018.060.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Stellungnahme zur Strahlentherapie mit Protononen in Deutschland. Deutsche Gesellschaft für Radioonkologie (DEGRO). Juni 2015. [online] Dostupné z: www.degro.org
    2. Proton beam therapy for cancer of the prostate. 13 July 2016. [online] Dostupné z: www.england.nhs.uk/commissioning/spec-services/npc-crg/group-b/b01/
    3. Chang JY, Jabbour SK, De Ruysscher D, et al. Consensus statent on proton therapy in early stage and locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2016; 95: 505-516. Go to original source... Go to PubMed...
    4. Dabaja BS, Mikhaeel NG. In the battle between protons and photons for hematologic malignancies, the patient must win. Int J Radiat Oncol Biol Phys 2016; 95: 43-45. Go to original source... Go to PubMed...
    5. Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early stage prostate cancer with IMRT and protons: A treatment planning comparison. Int J Radiat Oncol Biol Phys 2007; 69: 444-453. Go to original source... Go to PubMed...
    6. Vargas C, Fryer A, Mahajan C, et al. Dose - volume comparison of proton therapy and intensity modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 744-751. Go to original source... Go to PubMed...
    7. Chera BS, Vargas C, Morris CG, et al. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer. Int J radiat Oncol Biol Phys 2009; 75: 994-1002. Go to original source... Go to PubMed...
    8. Yoon M, Ahn SH, Kim J, et al. Radiation induced cancers from modern radiotherapy techn iques: intensity-modulated radiotherapy versus proton therapy. Int J Radiat Oncol Biol Phys 2010; 77: 1477-1485. Go to original source... Go to PubMed...
    9. Moon DH, Efstathiou JA, Chen RC. What is the best way to radiate the prostate in 2016? Urologic Oncology-Seminars and Original investigations 2017; 35: 59-68. Go to original source... Go to PubMed...
    10. NCCN Guidelines: Prostate cancer. Version 2.2018 - March 2018. [online] Dostupné z: www.nccn.org
    11. Coen JJ, Bac K, Zietman AL, et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys 2011; 81: 1005-1009. Go to original source... Go to PubMed...
    12. Nihei K, Ogino T, Onozawa M, et al. Multi-institutional phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. Int J Radiat Oncol BBiol Phys 2011; 81: 390-396. Go to original source... Go to PubMed...
    13. Mendenhall NP, Hoppe BS, Nichols RC, et al. Five-year outcomes form 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2014; 88: 596-602. Go to original source... Go to PubMed...
    14. Slater JD, Rosii CCJ, Yonemoto LT, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 2004; 59: 348-352. Go to original source... Go to PubMed...
    15. Fang P, Mick R, Deville C, et al. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer 2015; 121: 1118-1127. Go to original source... Go to PubMed...
    16. Gray OJ, Paly JJ, Yeap BY, et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 2013; 119: 1729-1735. Go to original source... Go to PubMed...
    17. Hoppe BS, Michalski JM, Mendenhall NP, et al. Comparative effectiveness study of patient - reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 2014; 120: 1076-1082. Go to original source... Go to PubMed...
    18. Sheets NC, Goldin GH, Meyer AM, et al. Intensity - modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. J Am Med Assoc 2012; 307: 38-45. Go to original source...
    19. Kim S, Shen S, Moore DF, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol 2011; 60: 908-916. Go to original source... Go to PubMed...
    20. Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 2013; 105: 25-32. Go to original source... Go to PubMed...
    21. Bryant C, Smith TL, Henderson RH, et al. Five year biochemical results, toxicity and patients reported quality of life after delivery of dose excalated image guided proton therapy for prostate cancer. IJROBF, 2016; 95: 422-434. Go to original source...
    22. Broul M, Štrbavý M, Skála P. Hodnocení erektilní dysfunkce po roboticky asistované radikální prostatektomii. Ces Urol 2014; 18: 324-333.
    23. Broďák M, Košina J, Balík M, et al. Robotem asistovaná radikální prostatektomie, zkušenosti po provedení prvních 50 operací. Urol. praxi 2017; 18: 129-132. Go to original source...
    24. Kokoška V, Schraml J, Nalos D, et al. Roboticky asistovaná radikální prostatektomie z pohledu anesteziologa a intenzivisty. Urol. praxi 2012; 13: 17-21.
    25. Guidelines on Prostate Cancer [online]. European Association of Urology 2015. Dostupné z: www.uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf
    26. Doporučné postupy v uroonkologii [online]. Dostupné z: www.cus.cz//pro-odborniky/vzdelavani/materialy/doporucne-postupy-v-uroonkologii/
    27. ASTRO updates insurance coverage recommendations for proton therapy [online]. [2017-07-13]. Dostupné z: www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2017/ASTRO-updates-insurance-coverage-recommendations-for-proton-therapy/
    28. Pedersen J, Petersen JBB, Stokkev?g CH, et al. Biological dose and complication probabilities for the rectum and bladder based on linear energy transfer distributions in spot scanning proton therapy of prostate cancer. Acta Oncol 2017; 56: 1413-1419. Go to original source... Go to PubMed...
    29. Khmelevsky EV, Kancheli IN, Khoroshkov VS, Kaprin AD. Morbidity dynamics in proton-photon or photon radiation therapy for locally advanced prostate cancer. Rep Pract Oncol Radiother 2018; 23: 21-27. Go to original source... Go to PubMed...
    30. Matoušková M. Gastrointestinální toxicita protonové léčby karcinomu prostaty. Ces Urol 2015; 19(Suppl. B): 77.
    31. Pokorný J, Končický P, Jirásek E, et al. Nekróza močového měchýře po radioterapii protonovým svazkem pro karcinom prostaty. Ces Urol 2016; 20 (Suppl. A): 90.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.